Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)
- Authors:
- Lei Zhan
- Xiaojing Liu
- Jing Zhang
- Yunxia Cao
- Bing Wei
-
Affiliations: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China - Published online on: June 25, 2020 https://doi.org/10.3892/ol.2020.11774
- Pages: 2075-2090
-
Copyright: © Zhan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Van Arsdale A, Miller DT, Kuo DY, Isani S, Sanchez L and Nevadunsky NS: Association of obesity with survival in patients with endometrial cancer. Gynecol Oncol. 154:156–162. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X and Wang J: The Role of Metabolic Syndrome in Endometrial Cancer: A Review. Front Oncol. 9:7442019. View Article : Google Scholar : PubMed/NCBI | |
|
Lynch HT, Snyder CL, Shaw TG, Heinen CD and Hitchins MP: Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 15:181–194. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, et al: Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 21:1041–1051. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial cancer. Lancet. 387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI | |
|
Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE and Köbel M: Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 26:1594–1604. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A and Gallo D: Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch. 457:27–34. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al Cancer Genome Atlas Research Network, : Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, et al: Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 123:802–813. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, et al: A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 113:299–310. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, et al: Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 29:1180–1188. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR and Kim JW: Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol. 30:e182019. View Article : Google Scholar : PubMed/NCBI | |
|
Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL and Haanen J: Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 15:457–472. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dracopoli NC and Boguski MS: The evolution of oncology companion diagnostics from signal transduction to immuno-oncology. Trends Pharmacol Sci. 38:41–54. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE III, Wistuba I, Chaft J, Rizvi NA, et al: Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci USA. 115:E10119–E10126. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al: Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 379:722–730. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vanderstraeten A, Tuyaerts S and Amant F: The immune system in the normal endometrium and implications for endometrial cancer development. J Reprod Immunol. 109:7–16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Deligdisch L: Morphologic correlates of host response in endometrial carcinoma. Am J Reprod Immunol. 2:54–57. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Silverberg SG, Sasano N and Yajima A: Endometrial carcinoma in Miyagi Prefecture, Japan: Histopathologic analysis of a cancer registry-based series and comparison with cases in American women. Cancer. 49:1504–1510. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK and Ochiel DO: Sex hormone regulation of innate immunity in the female reproductive tract: The role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol. 63:544–565. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pascual-García M, Bértolo C, Nieto JC, Serrat N, Espinosa Í, D'Angelo E, Muñoz R, Rovira R, Vidal S and Prat J: CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas. Hum Pathol. 56:180–188. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kondratiev S, Sabo E, Yakirevich E, Lavie O and Resnick MB: Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 10:4450–4456. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chang WC, Li CH, Huang SC, Chang DY, Chou LY and Sheu BC: Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma. Cancer. 116:5777–5788. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K and Aoki D: Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. 21:1628–1634. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al: Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 40:274–288. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Q and Jewell CM: Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. Curr Opin Biotechnol. 60:138–145. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dun EC, Hanley K, Wieser F, Bohman S, Yu J and Taylor RN: Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 32:576–584. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Weber SK, Sauerwald A, Pölcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G and Rudlowski C: Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer. 22:1442–1448. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kübler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, Mallmann MR, Kaiser C, Serçe NB, Kuhn W, et al: Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol. 135:176–183. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris N, Valensise H and Romanini C: The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II endometrial carcinoma. Acta Obstet Gynecol Scand. 73:652–657. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Garzetti GG, Ciavattini A, Goteri G, Tranquilli AL, Muzzioli M, Fabris N, De Nictolis M and Romanini C: Natural killer cell activity in stage I endometrial carcinoma: Correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol. 55:111–114. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Versluis MA, Marchal S, Plat A, de Bock GH, van Hall T, de Bruyn M, Hollema H and Nijman HW: The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment. Eur J Cancer. 86:285–295. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Zhu YB, Qu QX, Ge Y, Huang JA, Wang Y and Zhang XG: CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: Involvement of up-regulation of B7-H3 expression. J Immunother. 32:29–35. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lijun Z, Xin Z, Danhua S, Xiaoping L, Jianliu W, Huilan W and Lihui W: Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int J Gynecol Cancer. 22:836–841. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jia J, Wang Z, Li X, Wang Z and Wang X: Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 160:223–227. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zinovkin D and Pranjol MZ: Tumor-infiltrated lymphocytes, macrophages, and dendritic cells in endometrioid adenocarcinoma of corpus uteri as potential prognostic factors: An immunohistochemical study. Int J Gynecol Cancer. 26:1207–1212. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue T, Adachi K, Kawana K, Taguchi A, Nagamatsu T, Fujimoto A, Tomio K, Yamashita A, Eguchi S, Nishida H, et al: Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. Int J Oncol. 49:1297–1304. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kerr J, Anderson C and Lippman SM: Physical activity, sedentary behaviour, diet, and cancer: An update and emerging new evidence. Lancet Oncol. 18:e457–e471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ni L and Dong C: New checkpoints in cancer immunotherapy. Immunol Rev. 276:52–65. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Curran CS, Gupta S, Sanz I and Sharon E: PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 97:1–9. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H-T, Ahmed R and Okazaki T: Role of PD-1 in regulating T-cell immunity. 350:17–37. 2010. | |
|
Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S and Amant F: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. Cancer Immunol Immunother. 63:545–557. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, Yang S, Li H, Zhou L and You Z: Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 12:944–950. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kim S, Lee HS, Yang W, Cho H, Chay DB, Cho SJ, Hong S and Kim JH: Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecol Oncol. 149:381–387. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP and Zang X: The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7×, and B7-H3. Immunol Rev. 276:26–39. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Brunner A, Hinterholzer S, Riss P, Heinze G and Brustmann H: Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis. Gynecol Oncol. 124:105–111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 106:119–127. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB and Rueda BR: Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol. 145:446–452. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R and Pirro M: Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 196:105–116. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
de Jong RA, Kema IP, Boerma A, Boezen HM, van der Want JJ, Gooden MJ, Hollema H and Nijman HW: Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol. 126:474–480. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O and Kikkawa F: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin Cancer Res. 14:2310–2317. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC and Ring KL: Indoleamine 2,3-dioxygenase in endometrial cancer: A targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 31:1282–1290. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Calviño-Sampedro C, Gomez-Tourino I, Cordero OJ, Reche PA, Gómez-Perosanz M, Sánchez-Trincado JL, Rodríguez MÁ, Sueiro AM, Viñuela JE and Calviño RV: Naturally presented HLA class I-restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes. FASEB J. 33:6390–6401. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, Kloetzel PM, Stumpf MP, Heck AJ and Mishto M: A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science. 354:354–358. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359:582–587. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
de Jong RA, Boerma A, Boezen HM, Mourits MJE, Hollema H and Nijman HW: Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer. 131:1828–1836. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Barrier BF, Kendall BS, Sharpe-Timms KL and Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 103:25–30. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH and Nijman HW: The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 126:1417–1427. 2010.PubMed/NCBI | |
|
Lin A and Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 9:21642018. View Article : Google Scholar : PubMed/NCBI | |
|
Ben Yahia H, Babay W, Bortolotti D, Boujelbene N, Laaribi AB, Zidi N, Kehila M, Chelbi H, Boudabous A, Mrad K, et al: Increased plasmatic soluble HLA-G levels in endometrial cancer. Mol Immunol. 99:82–86. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T and Nakano H: Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol Oncol. 97:772–779. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nakashima M, Sonoda K and Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med. 5:938–942. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Giaginis C, Giagini A and Theocharis S: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): A novel biomarker in the diagnosis and prognosis of human neoplasia. Histol Histopathol. 24:761–776. 2009.PubMed/NCBI | |
|
Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T and Nakano H: The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol. 79:424–429. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sonoda K, Miyamoto S, Hirakawa T, Kaku T, Nakashima M, Watanabe T, Akazawa K, Fujita T and Nakano H: Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br J Cancer. 89:546–551. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Szubert S, Koper K, Dutsch-Wicherek MM and Kojs Z: The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer. Ginekol Pol. 90:134–140. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rand AA, Barnych B, Morisseau C, Cajka T, Lee KS, Panigrahy D and Hammock BD: Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Proc Natl Acad Sci USA. 114:4370–4375. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Elling R, Robinson EK, Shapleigh B, Liapis SC, Covarrubias S, Katzman S, Groff AF, Jiang Z, Agarwal S, Motwani M, et al: Genetic models reveal cis and trans immune-regulatory activities for lincRNA-Cox2. Cell Reports. 25:1511–1524.e1516. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang H, Liu Y, Wang C, Zheng H, Chen Y, Liu W, Chen X, Zhang J, Chen H, Yang Y, et al: Inhibition of COX-2 and EGFR by melafolone improves anti-PD-1 therapy through vascular normalization and PD-L1 downregulation in lung cancer. J Pharmacol Exp Ther. 368:401–413. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G and Inoue M: Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer. 114:696–701. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Suemori T, Susumu N, Iwata T, Banno K, Yamagami W, Hirasawa A, Sugano K, Matsumoto E and Aoki D: Intratumoral CD8+ lymphocyte infiltration as a prognostic factor and its relationship with cyclooxygenase 2 expression and microsatellite instability in endometrial cancer. Int J Gynecol Cancer. 25:1165–1172. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ols ML, Cullen JL, Turqueti-Neves A, Giles J and Shlomchik MJ: Dendritic cells regulate extrafollicular autoreactive B cells via T cells expressing Fas and Fas ligand. Immunity. 45:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K and Nishimura R: Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer. 82:1682–1688. 2000.PubMed/NCBI | |
|
Jia JJ, Wang ZN, Liu GX and Wang ZX: Apoptosis and expression of Fas/FasL in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 31:1693–1696. 2011.(In Chinese). PubMed/NCBI | |
|
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, et al: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 117:788–797. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Végran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S and Boidot R: Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res. 73:5391–5401. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Liu Y and Liu M: Platelet-rich plasma injection is not more effective than hyaluronic acid to treat knee osteoarthritis when using a random-effects model. Br J Sports Med. 50:953–954. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, et al: Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol. 141:564–569. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A, Sirohi VK, Anum F, Singh PK, Gupta K, Gupta D, Saraf SA, Dwivedi A and Chourasia MK: Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer. Nanomedicine (Lond). 13:1953–1963. 2017. View Article : Google Scholar | |
|
Kang S, Tanaka T, Narazaki M and Kishimoto T: Targeting Interleukin-6 Signaling in Clinic. Immunity. 50:1007–1023. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S and Santin AD: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 98:92–98. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK and Wu J: JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 3:30422013. View Article : Google Scholar : PubMed/NCBI | |
|
Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, Yu L and Chmielecki J: Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 12:e01761812017. View Article : Google Scholar : PubMed/NCBI | |
|
Chao A, Tang YH, Lai CH, Chang CJ, Chang SC, Wu TI, Hsueh S, Wang CJ, Chou HH and Chang TC: Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol Oncol. 129:500–504. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J and Sun J: MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment. OncoImmunology. 7:e14879142018. View Article : Google Scholar : PubMed/NCBI | |
|
Grotzke JE, Sengupta D, Lu Q and Cresswell P: The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation. Curr Opin Immunol. 46:89–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Li H, Xiao C, Zeng X, Xiao X, Zhou Q and Xiao P: NLRC5: Potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis. J Transl Med. 16:3172018. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA and Kobayashi KS: NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci USA. 113:5999–6004. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A and Kiessling R: Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 73:3877–3887. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK and Dubinett SM: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65:5211–5220. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
St-Germain ME, Gagnon V, Parent S and Asselin E: Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer. 3:72004. View Article : Google Scholar : PubMed/NCBI | |
|
Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, et al: VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 120:115–127. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zsiros E and Odunsi K: Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma. Gynecol Oncol. 135:173–175. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677–686. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, et al: Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res. 14:7251–7259. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Check JH and Cohen R: The role of progesterone and the progesterone receptor in human reproduction and cancer. Expert Rev Endocrinol Metab. 8:469–484. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Huang F, Mei J, Wang X, Zhang Q, Wang H, Xi M and You Z: Posttranscriptional control of PD-L1 expression by 17β-estradiol via PI3K/Akt signaling pathway in ERα-positive cancer cell lines. Int J Gynecol Cancer. 27:196–205. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ning C, Xie B, Zhang L, Li C, Shan W, Yang B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce ERα expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen. Cancer Res. 76:1354–1366. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, et al: Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol. 27:5270–5277. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, et al: Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 29:4779–4784. 2009.PubMed/NCBI | |
|
Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, et al: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA. 103:14453–14458. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol. 35:2535–2541. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Osterman C, McCarthy MBR, Cote MP, Beitzel K, Bradley J, Polkowski G and Mazzocca AD: Platelet-rich plasma increases anti-inflammatory markers in a human coculture model for osteoarthritis. Am J Sports Med. 43:1474–1484. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 344:641–645. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, et al: Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1–2 trial. Lancet Oncol. 20:383–393. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, et al: PRIMMO study protocol: A phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer. 19:5062019. View Article : Google Scholar : PubMed/NCBI | |
|
Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH and Yates MS: Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. 23:4473–4481. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Temko D, Van Gool IC, Rayner E, Glaire M, Makino S, Brown M, Chegwidden L, Palles C, Depreeuw J, Beggs A, et al: Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 245:283–296. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, et al: Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology. 6:e12645652016. View Article : Google Scholar : PubMed/NCBI | |
|
Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, Anglesio MS, Nelson BH and McAlpine JN: Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 25:2537–2548. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mullen MM and Mutch DG: Endometrial tumor immune response: Predictive biomarker of response to immunotherapy. Clin Cancer Res. 25:2366–2368. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH and Albelda SM: Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63:7845–7852. 2003.PubMed/NCBI | |
|
Han Y, Qin W and Huang G: Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation. Cancer Lett. 257:182–190. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, et al: hI-con1, a factor VII–IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 103:812–819. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 117:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vanderstraeten A, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F and Tuyaerts S: In vitro validation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer. J Immunother. 38:239–249. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, et al: A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 26:2141–2149. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rader JS, Aylsworth CF, Juckett DA, Mutch DG, Powell MA, Lippmann L and Dimitrov NV: Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res. 14:3089–3097. 2008. View Article : Google Scholar : PubMed/NCBI |
